Cardiol Therapeutics Expands MAVERIC Trial Network

Cardiol Therapeutics Inc. has announced a significant expansion in its Phase III MAVERIC trial for recurrent pericarditis in the United States. The company plans to add up to seven new clinical centers, increasing the total number of sites to approximately 25. As of now, enrolment has reached 75%, with a full-enrolment target set by Q2/26, allowing some flexibility into Q3/26 to accommodate an inflow from newly activated sites.

The trial involves prestigious institutions such as the Cleveland Clinic, Mayo Clinic campuses, and Massachusetts General Hospital. Their participation underscores the trial's credibility, reflecting confidence in its therapeutic rationale and addressing an unmet need in recurrent pericarditis treatment. This expansion diversifies the dataset geographically and institutionally, strengthening the case for New Drug Application submission.

Cardiol's current stock target is USD 7.50, with the MAVERIC trial results seen as a pivotal point for valuation over the coming year.